Carteolol; Mechanism, Uses, Contraindications, Dosage, Side effects, Interaction Carteolol is a synthetic quinolinone derivative and nonselective beta-adrenoceptor blocking agent with anti-glaucoma activity. Upon topical administration to the eye, carteolol decreases aqueous humor production, thereby reducing intraocular pressure (IOP).A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-anginal agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol is only found in individuals that have used or taken this drug. It is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-anginal agent, an antihypertensive agent, and an antiglaucoma agent. The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade. Mechanism of Action of Carteolol The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade. Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce. Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce. You Might Also Read Aspirin Contraindications, Pregnancy CategoryIndications of Carteolol Increased intraocular pressure Treatment of intraocular hypertension and chronic open-angle glaucoma Lowering of intraocular pressure in patients with chronic open-angle glaucoma and intraocular hypertension Dosage of Carteolol Strengths: 1% Intraocular Hypertension One drop in the affected eye(s) twice a day Glaucoma (Open Angle) One drop in the affected eye(s) twice a day ……………….Details coming soon References DrugBank http://www.drugbank.ca/drugs/DB00521 http://www.drugbank.ca/drugs/DB00521#targets http://www.drugbank.ca/drugs/DB00521#enzymes EPA DSStox https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID3022746 Human Metabolome Database (HMDB) http://www.hmdb.ca/metabolites/HMDB0014662 NCIT https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C65291 FDA Orange Book https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm NIST http://www.nist.gov/srd/nist1a.cfm PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0000334/ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009476/ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0009477/ Springer Nature Read more … https://pubchem.ncbi.nlm.nih.gov/substance/341309125 WHO ATC https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ Wikipedia https://en.wikipedia.org/wiki/Carteolol https://pubchem.ncbi.nlm.nih.gov